Gambro ends Japanese joint venture to sell independently
This article was originally published in Clinica
Swedish company Gambro is to go it alone in Japan, having broken off its sales joint venture with Teijin Medical in the second largest dialysis market after the US. As a result, Gambro will lose revenues of SEK200 million ($24 million), although it says the impact on profits will be insignificant. The joint venture, Gambro Teijin Medical, will be dissolved in December, by mutual agreement.